“Calidi (CLDI) continues to make great progress on all three of our platforms;our systemic asset CLD-400 proved it can deliver a gene therapy payload to targeted tumors, we filed an IND for our solid tumor asset CLD-201, and our CLD-101 program treating high-grade glioma is advancing in two Phase 1 trials,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. “We think our multi-modal mechanism of action is a game changer in treating multiple deadly cancers, including metastatic cancer and lung cancer, solid tumors and high-grade glioma.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi prices 3.33M shares at 65c in registered direct offering
- Calidi, City of Hope provide update on Phase 1 trial with CLD-101
- Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform
- Calidi Biotherapeutics Announces Promising Preclinical Results
- Calidi announces ability to deliver transient gene therapy to tumors